牛牛AI助理已提取核心訊息
Eli Lilly and Company (LLY.US), a leading pharmaceutical company, has announced the issuance of a series of new notes under a preliminary prospectus supplement dated February 7, 2024. The offering includes multiple tranches of notes with varying maturity dates and interest rates, payable semi-annually. The notes, unsecured and unsubordinated debt obligations, will rank equally with other unsecured indebtedness of the company. The aggregate principal amount, interest rates, maturity dates, and other specific terms of the notes will be determined at the time of sale. The notes are being offered through a group of joint book-running managers, including BofA Securities, Barclays, Citigroup, Deutsche Bank Securities, and Mizuho. The proceeds from the sale of the notes are intended for general corporate purposes, which may include debt repayment and refinancing. The notes will not be listed on any securities exchange, and the underwriters expect to deliver them to investors in book-entry form through The Depository Trust Company on or about a specified date in 2024.
Eli Lilly and Company (LLY.US), a leading pharmaceutical company, has announced the issuance of a series of new notes under a preliminary prospectus supplement dated February 7, 2024. The offering includes multiple tranches of notes with varying maturity dates and interest rates, payable semi-annually. The notes, unsecured and unsubordinated debt obligations, will rank equally with other unsecured indebtedness of the company. The aggregate principal amount, interest rates, maturity dates, and other specific terms of the notes will be determined at the time of sale. The notes are being offered through a group of joint book-running managers, including BofA Securities, Barclays, Citigroup, Deutsche Bank Securities, and Mizuho. The proceeds from the sale of the notes are intended for general corporate purposes, which may include debt repayment and refinancing. The notes will not be listed on any securities exchange, and the underwriters expect to deliver them to investors in book-entry form through The Depository Trust Company on or about a specified date in 2024.
領先的製藥公司禮來公司（LLY.US）宣佈根據2024年2月7日的初步招股說明書補充文件發行一系列新票據。本次發行包括多批到期日和利率不同的票據，每半年支付一次。這些票據，包括無抵押和非次級債務，將與公司的其他無抵押債務同等地位。票據的本金總額、利率、到期日和其他具體條款將在出售時確定。這些票據由包括美銀證券、巴克萊、花旗集團、德意志銀行證券和瑞穗在內的多家聯席賬簿管理公司發行。出售票據的收益用於一般公司用途，其中可能包括債務償還和再融資。這些票據不會在任何證券交易所上市，承銷商預計將在2024年的指定日期或前後通過存託信託公司以賬面記賬形式將其交付給投資者。
領先的製藥公司禮來公司（LLY.US）宣佈根據2024年2月7日的初步招股說明書補充文件發行一系列新票據。本次發行包括多批到期日和利率不同的票據，每半年支付一次。這些票據，包括無抵押和非次級債務，將與公司的其他無抵押債務同等地位。票據的本金總額、利率、到期日和其他具體條款將在出售時確定。這些票據由包括美銀證券、巴克萊、花旗集團、德意志銀行證券和瑞穗在內的多家聯席賬簿管理公司發行。出售票據的收益用於一般公司用途，其中可能包括債務償還和再融資。這些票據不會在任何證券交易所上市，承銷商預計將在2024年的指定日期或前後通過存託信託公司以賬面記賬形式將其交付給投資者。
有用
沒用